Sanofi at forefront of fight against COVID-19 in Q1 2020
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: PR Newswire
PARIS, April 24, 2020 /PRNewswire/ -- Sanofi (NASDAQ: SNY; EURONEXT: SAN)Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8719551-sanofi-earnings-results-q1-2020/ Rapid and decisive response to COVID-19 global health crisisSanofi showed resilience and maintained full business continuity worldwide including its global industrial network. Separate collaborations announced with BARDA, Translate Bio and GSK to develop novel COVID-19 vaccines. Global clinical program underway to evaluate Kevzara® in patients hospitalized with severe COVID-19. Initiated two studies evaluating hydroxychloroquine as a treatment for COVID-19. Commitment to donate 100 million doses. In addition, a leading European API company to be created to help balance the industry's reliance on API sourced from Asia.Q1 2020 sales growth performance driven by Dupixent® COVID-19 stocking in channels explains about half of company sales growth in Q1; Dupixent® growth unaffected
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Moderna And Other Vaccine Maker Stocks Tumble After Trump Taps RFK Jr. As HHS Head [Forbes]Forbes
- Measuring Cross-Platform Ad Effectiveness Using A Single-Source [Forbes]Forbes
- Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaGlobeNewswire
- Neuraxpharm reports another year of sustained growth and international expansion [Yahoo! Finance]Yahoo! Finance
- Diabetics left without treatment as global rate of disease doubles [Financial Times (FT.com) (UK)]Financial Times
SNY
Analyst Actions
- 9/19/24 - Citigroup Inc.
SNY
Sec Filings
- 11/7/24 - Form SC
- 11/7/24 - Form 6-K
- 10/31/24 - Form 6-K
- SNY's page on the SEC website